We demonstrated in a phase I/II clinical trial that autologous dendritic cells (DCs) loaded with the tumor-associated antigen (TAA) Wilms’ tumor 1 (WT1) by mRNA electroporation can induce clinical responses in AML patients with very limited side effects [2]. Here, WT1 is linked to acute myeloid leukemia.